FERACCRU® had a consistently good tolerability profile1,2
Fewer than 1 in 4 patients had treatment-related AEs during long-term treatment2
AEs were mainly mild to moderate in severity and gastrointestinal in nature1,2
Just 7% of patients discontinued FERACCRU® due to treatment-related AEs2
FERACCRU® was well tolerated throughout long-term treatment despite 2/3 patients previously failing with oral ferrous iron salts due to AEs1,2
AEGIS-IBD long-term open label study design1,2
Primary endpoint2
- Change in Hb from baseline to Week 64 (12 plus 52 weeks)
Secondary endpoints2
- Proportion of patients achieving normal Hb levels
- Serum ferritin concentration and percentrage TSAT
- Disease-specific QoL
FERACCRU® had no negative impact on patients’ QoL or IBD severity1,2
AE, adverse event; CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; CKD, chronic kidney disease; Hb, haemoglobin; IBD, inflammatory bowel disease; IDA, iron deficiency anaemia; QoL, quality of life; SCCAI, Simple Clinical Colitis Activity Index; TSAT, transferrin saturation; UC, ulcerative colitis.
References:
- Gasche C, et al. Inflamm Bowel Dis 2015;21(3):579–588.
- Schmidt C, et al. Aliment Pharmacol Ther 2016;44(3):259–270.
